Matches in SemOpenAlex for { <https://semopenalex.org/work/W2956654235> ?p ?o ?g. }
- W2956654235 endingPage "1622" @default.
- W2956654235 startingPage "1595" @default.
- W2956654235 abstract "Cardiovascular disease (CVD), including heart failure (HF), is a leading cause of morbidity and mortality in people with type 2 diabetes mellitus (T2DM). CVD and T2DM share common risk factors for development and progression, and there is significant overlap between the conditions in terms of worsening outcomes. In assessing the cardiovascular (CV) safety profiles of anti-diabetic drugs, sodium-glucose co-transporter-2 inhibitor (SGLT2i) therapies have emerged with robust evidence for reducing the risk of adverse CVD outcomes in people with T2DM who have either established CVD or are at risk of developing CVD. A previous consensus document from the Improving Diabetes Steering Committee has examined the potential role of SGLT2is in T2DM management and considered the risk–benefit profile of the class and the appropriate place for these medicines within the T2DM pathway. This paper builds on these findings and presents practical guidance for maximising the pleiotropic benefits of this class of medicines in people with T2DM in terms of reducing adverse CVD outcomes. The Improving Diabetes Steering Committee aims to offer evidence-based practical guidance for the use of SGLT2i therapies in people with T2DM stratified by CVD risk. This is of particular importance currently because some treatment guidelines have not been updated to reflect recent evidence from cardiovascular outcomes trials (CVOTs) and real-world studies that complement the CVOTs. The Improving Diabetes Steering Committee seeks to support healthcare professionals (HCPs) in appropriate treatment selection for people with T2DM who are at risk of developing or have established CVD and examines the role of SGLT2i therapy for these people. Funding: Napp Pharmaceuticals Limited." @default.
- W2956654235 created "2019-07-23" @default.
- W2956654235 creator A5008349163 @default.
- W2956654235 creator A5036297052 @default.
- W2956654235 creator A5040238276 @default.
- W2956654235 creator A5043785693 @default.
- W2956654235 creator A5047195042 @default.
- W2956654235 creator A5049407467 @default.
- W2956654235 creator A5053232051 @default.
- W2956654235 creator A5069283391 @default.
- W2956654235 creator A5070756199 @default.
- W2956654235 creator A5078488183 @default.
- W2956654235 creator A5087683934 @default.
- W2956654235 date "2019-07-09" @default.
- W2956654235 modified "2023-10-16" @default.
- W2956654235 title "SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice" @default.
- W2956654235 cites W1526927233 @default.
- W2956654235 cites W172609984 @default.
- W2956654235 cites W1809230663 @default.
- W2956654235 cites W1849517704 @default.
- W2956654235 cites W1877394668 @default.
- W2956654235 cites W1912371921 @default.
- W2956654235 cites W1983269691 @default.
- W2956654235 cites W1988728194 @default.
- W2956654235 cites W2006804028 @default.
- W2956654235 cites W2008657120 @default.
- W2956654235 cites W2021976026 @default.
- W2956654235 cites W2023938374 @default.
- W2956654235 cites W2028317115 @default.
- W2956654235 cites W2042693868 @default.
- W2956654235 cites W2053091858 @default.
- W2956654235 cites W2053365438 @default.
- W2956654235 cites W2064130493 @default.
- W2956654235 cites W2083801759 @default.
- W2956654235 cites W2094065060 @default.
- W2956654235 cites W2101382476 @default.
- W2956654235 cites W2105744242 @default.
- W2956654235 cites W2106555525 @default.
- W2956654235 cites W2108103091 @default.
- W2956654235 cites W2108292236 @default.
- W2956654235 cites W2110664743 @default.
- W2956654235 cites W2118619033 @default.
- W2956654235 cites W2120729896 @default.
- W2956654235 cites W2123946565 @default.
- W2956654235 cites W2125653714 @default.
- W2956654235 cites W2126483958 @default.
- W2956654235 cites W2127125241 @default.
- W2956654235 cites W2136919786 @default.
- W2956654235 cites W2140429097 @default.
- W2956654235 cites W2142593697 @default.
- W2956654235 cites W2146264128 @default.
- W2956654235 cites W2149681568 @default.
- W2956654235 cites W2150561315 @default.
- W2956654235 cites W2154067841 @default.
- W2956654235 cites W2158666727 @default.
- W2956654235 cites W2168205528 @default.
- W2956654235 cites W2218951533 @default.
- W2956654235 cites W2282578582 @default.
- W2956654235 cites W2407467502 @default.
- W2956654235 cites W2412117889 @default.
- W2956654235 cites W2412800896 @default.
- W2956654235 cites W2425644022 @default.
- W2956654235 cites W2436309489 @default.
- W2956654235 cites W2492672367 @default.
- W2956654235 cites W2509726330 @default.
- W2956654235 cites W2519510391 @default.
- W2956654235 cites W2580928085 @default.
- W2956654235 cites W2583804535 @default.
- W2956654235 cites W2594590765 @default.
- W2956654235 cites W2604392184 @default.
- W2956654235 cites W2605650980 @default.
- W2956654235 cites W2611049468 @default.
- W2956654235 cites W2614137535 @default.
- W2956654235 cites W2626446274 @default.
- W2956654235 cites W2730107310 @default.
- W2956654235 cites W2743267681 @default.
- W2956654235 cites W2754041380 @default.
- W2956654235 cites W2756191633 @default.
- W2956654235 cites W2760952310 @default.
- W2956654235 cites W2766166596 @default.
- W2956654235 cites W2766389943 @default.
- W2956654235 cites W2766605127 @default.
- W2956654235 cites W2766754230 @default.
- W2956654235 cites W2768451744 @default.
- W2956654235 cites W2770196824 @default.
- W2956654235 cites W2772844083 @default.
- W2956654235 cites W2777213061 @default.
- W2956654235 cites W2779223875 @default.
- W2956654235 cites W2782920834 @default.
- W2956654235 cites W2783270596 @default.
- W2956654235 cites W2786858141 @default.
- W2956654235 cites W2790066766 @default.
- W2956654235 cites W2793355388 @default.
- W2956654235 cites W2793795908 @default.
- W2956654235 cites W2800123898 @default.
- W2956654235 cites W2801850987 @default.
- W2956654235 cites W2805417982 @default.
- W2956654235 cites W2805917372 @default.